{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:10:09Z","timestamp":1793725809263,"version":"4.6.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T00:00:00Z","timestamp":1546819200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12883-018-1220-3","type":"journal-article","created":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T05:21:18Z","timestamp":1546838478000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries"],"prefix":"10.1186","volume":"19","author":[{"given":"Takahiko","family":"Saida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jang","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalitha","family":"Mahadavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah I.","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,7]]},"reference":[{"key":"1220_CR1","doi-asserted-by":"crossref","unstructured":"Gold R, Kappos L, Arnold DL. Bar-or A, Giovannoni G, Selmaj K, et al; DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098\u2013107.","DOI":"10.1056\/NEJMoa1114287"},{"key":"1220_CR2","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","volume":"367","author":"RJ Fox","year":"2012","unstructured":"Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al.; CONFIRM study investigators. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367:1087\u201397.","journal-title":"N Engl J Med"},{"key":"1220_CR3","first-page":"422","volume":"22","author":"JT Tibung","year":"2016","unstructured":"Tibung JT, Nestorov I, McNeill M, Li J, Zhu B. An open-label, parallel-group, phase 1 study to evaluate the pharmacokinetics, safety, and tolerability of dimethyl fumarate in Chinese, Japanese, and Caucasian adult healthy volunteers. Mult Scler. 2016;22:422.","journal-title":"Mult Scler"},{"key":"1220_CR4","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s00415-006-0400-z","volume":"254","author":"I Nakashima","year":"2007","unstructured":"Nakashima I, Fukazawa T, Ota K, Nohara C, Warabi Y, Ohashi T, et al. Two subtypes of optic-spinal form of multiple sclerosis in Japan: clinical and laboratory features. J Neurol. 2007;254:488\u201392.","journal-title":"J Neurol"},{"key":"1220_CR5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/0022-510X(81)90083-6","volume":"49","author":"H Shibasaki","year":"1981","unstructured":"Shibasaki H, McDonald WI, Kuroiwa Y. Racial modification of clinical picture of multiple sclerosis: comparison between British and Japanese patients. J Neurol Sci. 1981;49:253\u201371.","journal-title":"J Neurol Sci"},{"key":"1220_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jns.2012.08.032","volume":"323","author":"H Houzen","year":"2012","unstructured":"Houzen H, Niino M, Hirotani M, Fukazawa T, Kikuchi S, Tanaka K, et al. Increased prevalence, incidence, and female predominance of multiple sclerosis in northern Japan. J Neurol Sci. 2012;323:117\u201322.","journal-title":"J Neurol Sci"},{"key":"1220_CR7","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/WCO.0000000000000328","volume":"29","author":"H Ochi","year":"2016","unstructured":"Ochi H, Fujihara K. Demyelinating diseases in Asia. Curr Opin Neurol. 2016;29:222\u20138.","journal-title":"Curr Opin Neurol"},{"key":"1220_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/1352458508098372","volume":"15","author":"M Osoegawa","year":"2009","unstructured":"Osoegawa M, Kira J, Fukazawa T, Fujihara K, Kikuchi S, Matsui M, et al. Research Committee of Neuroimmunological Diseases. Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese: nationwide survey results over 30 years. Mult Scler. 2009;15:159\u201373.","journal-title":"Mult Scler"},{"key":"1220_CR9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1097\/WCO.0000000000000315","volume":"29","author":"SH Kim","year":"2016","unstructured":"Kim SH, Kim HJ. Central nervous system neuroinflammatory disorders in Asian\/Pacific regions. Curr Opin Neurol. 2016;29:372\u201380.","journal-title":"Curr Opin Neurol"},{"key":"1220_CR10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International panel for NMO diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177\u201389.","journal-title":"Neurology"},{"key":"1220_CR11","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/ana.20703","volume":"58","author":"CH Polman","year":"2005","unstructured":"Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the \"McDonald criteria\". Ann Neurol. 2005;58:840\u20136.","journal-title":"Ann Neurol"},{"key":"1220_CR12","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444\u201352.","journal-title":"Neurology"},{"key":"1220_CR13","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","volume":"66","author":"DM Wingerchuk","year":"2006","unstructured":"Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66:1485\u20139.","journal-title":"Neurology"},{"key":"1220_CR14","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/S0140-6736(08)61619-0","volume":"372","author":"L Kappos","year":"2008","unstructured":"Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, et al. BG-12 phase IIb study investigators. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;372:1463\u201372.","journal-title":"Lancet"},{"key":"1220_CR15","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(13)70103-0","volume":"12","author":"MP Sormani","year":"2013","unstructured":"Sormani MP, Bruzzi P. MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurol. 2013;12:669\u201376.","journal-title":"Lancet Neurol"},{"key":"1220_CR16","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/ana.21464","volume":"64","author":"MP Sormani","year":"2008","unstructured":"Sormani MP, Tintore M, Rovaris M, Rovira A, Vidal X, Bruzzi P, et al. Will Rogers phenomenon in multiple sclerosis. Ann Neurol. 2008;64:428\u201333.","journal-title":"Ann Neurol"},{"key":"1220_CR17","doi-asserted-by":"crossref","unstructured":"Cook SD, Dhib-Jalbut S, Dowling P, Durelli L, Ford C, Giovannoni G, et al. Use of magnetic resonance imaging as well as clinical disease activity in the clinical classification of multiple sclerosis and assessment of its course: a report from an international CMSC consensus conference, March 5-7, 2010. Int J MS Care. 2012;14:105\u201314.","DOI":"10.7224\/1537-2073-14.3.105"},{"key":"1220_CR18","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/ene.12624","volume":"22","author":"L Kappos","year":"2015","unstructured":"Kappos L, Giovannoni G, Gold R, Phillips JT, Arnold DL, Hotermans C, et al. DEFINE and CONFIRM study investigators. Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis. Eur J Neurol. 2015;22:664\u201371.","journal-title":"Eur J Neurol"},{"key":"1220_CR19","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1212\/CPJ.0000000000000238","volume":"6","author":"RJ Fox","year":"2016","unstructured":"Fox RJ, Chan A, Gold R, Phillips JT, Selmaj K, Chang I, et al. Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: patient management considerations. Neurol Clin Pract. 2016;6:220\u20139.","journal-title":"Neurol Clin Pract"},{"key":"1220_CR20","doi-asserted-by":"publisher","first-page":"236","DOI":"10.7224\/1537-2073.2014-069","volume":"17","author":"JT Phillips","year":"2015","unstructured":"Phillips JT, Selmaj K, Gold R, Fox RJ, Havrdova E, Giovannoni G, et al. Clinical significance of gastrointestinal and flushing events in patients with multiple sclerosis treated with delayed-release dimethyl fumarate. Int J MS Care. 2015;17:236\u201343.","journal-title":"Int J MS Care"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-018-1220-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12883-018-1220-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-018-1220-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T19:09:16Z","timestamp":1578337756000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-018-1220-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,7]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1220"],"URL":"https:\/\/doi.org\/10.1186\/s12883-018-1220-3","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,7]]},"assertion":[{"value":"27 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by ethics committees and conducted in accordance with the International Conference on Harmonisation Guidelines for Good Clinical Practice and the Declaration of Helsinki. Each site used a different ethics committee (detailed in Additional file  IRB Table). Written informed consent was obtained from each patient before any protocol-specific procedure.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TS was a coordinating investigator and has received funding from, held board membership for, spoken at scientific meetings for, prepared manuscripts for, and had consulting agreements with Astellas, Biogen, Bayer-Schering, Daiichi-Sankyo, Eisai, Kaketsuken, Merck Serono, Mitsubishi-Tanabe, Nihon, Novartis, Ono, Sanofi, TDS Japan, and Teijin.TY (Multiple Sclerosis Center, National Center of Neurology and Psychiatry) is a member of scientific advisory boards for Biogen and Chugai; received research support from Asahi Kasei Kuraray, Chugai, Mitsubishi Tanabe, Ono, and Teva; received speaker honoraria from Abbot Japan, Astellas, Bayer, Biogen, Dainippon Sumitomo, Eisai, Mitsubishi Tanabe, Nihon, Novartis, and Santen; and is funded by the Japanese Ministry of Health, Labour and Welfare and the Japan Society for the Promotion of Science.TK has received research support from Bayer HealthCare, Biogen, Eisai, Mitsubishi Tanabe, Novartis, and Takeda, and speaker honoraria from Bayer, Biogen, Daiichi Sankyo, Eisai, Mitsubishi Tanabe, and Novartis.JY, MY, LM, BZ, and SIS are full-time employees of and hold stock\/stock options in Biogen.JL has nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"5"}}